Dr. Kelley Discusses Biomarkers for Immunotherapy in HCC

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma (HCC).

In the advent of immunotherapy in HCC, there has been a renewed interest in determining biomarkers to find patients best suited for this treatment.

Following in the footsteps of other gastrointestinal malignancies, biomarkers like mutation burden may be a useful indicator, Kelley says. It is still too early to know, adds Kelley, as more data need to be collected to make a distinct analysis.